News1

Hanyang University announced that Professor Lim Chang-hwan's team developed an AI model SPERA for analyzing sleep and emotional states.

CGBIO gains approval for calcium-based filler Facetem in Taiwan, aiming for over 5 billion KRW in sales within 3 years

Nvidia combines simulation platforms with robotics to overcome physical AI development limits and expand its ecosystem.

GS Caltex won two awards at the 2026 London International Advertising Awards with its CCU-S campaign promoting low-carbon technologies.

LS Electric supplies 140 million USD worth of power distribution equipment to a major U.S. tech data center.

Study shows reducing radiation therapy sessions from 33 to 26 maintains similar cancer suppression in prostate cancer patients.

Lunit has signed a strategic partnership with Discovery Life Sciences to combine its AI-powered pathology platform with the U.S. company’s biospecimen and analytical capabilities, supporting biomarker analysis and drug development for global pharmaceutical companies.

Incheon Naeun Hospital introduces a backup and recovery solution for medical data, marking the first implementation in South Korea.

Ildong Pharmaceutical seeks to expand drug exports and contract manufacturing at a global pharmaceutical exhibition in Milan.

Park Young-min emphasized the importance of global partnerships to translate promising research results into actual drug development.

Dongkook Pharmaceutical plans to change its name to DK Centellian, expanding into healthcare and beauty for global market growth.

Daewoong Bio expands its diagnostic business to detect Alzheimer's signs through blood tests, simplifying detection compared to existing methods.

HK inno.N’s U.S. partner Sebela Pharmaceuticals will present Phase 3 results for K-CAB in non-erosive gastroesophageal reflux disease, with the trial showing significant improvements in heartburn-free days at both tested doses.

HLB and its partners have resubmitted an application for rivoceranib and camrelizumab as a first-line liver cancer treatment, about three months after receiving an FDA Complete Response Letter, citing Phase 3 results showing a median overall survival of 23.8 months.